The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment

PHASE2TerminatedINTERVENTIONAL
Enrollment

125

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

January 31, 2015

Study Completion Date

February 11, 2015

Conditions
PainPeripheral NeuropathyNeuropathic Pain
Interventions
DRUG

Placebo

Sham treatment acting as control arm

DRUG

Tetrodotoxin

Comparison of different dosages of Tetrodotoxin

Trial Locations (23)

17325

Gettysburg Cancer Center, Gettysburg

20817

Center for Cancer and Blood Disorders, Bethesda

31021

Cancer Center of Middle Georgia, Dublin

33414

Axcess Medical Research, Wellington

33952

Medsol Clinical Research Center, Port Charlotte

45042

Signal Point Clinical Research Center, Middletown

63044

St. Louis Cancer Care, Bridgeton

65807

Mercy Medical Research Institute, Springfield

67214

Cancer Center of Kansas, Wichita

73104

Institute of Pain Research, Oklahoma City

84124

Jean Brown Research, Salt Lake City

87103

New Mexico Oncology Hematology Consultants, Albuquerque

90027

Global Research Management, Los Angeles

90603

Innovative Clinical Research, Los Angeles

92653

Alliance Research Centers, Laguna Hills

92708

Lalita Pandit, Fountain Valley

Robert Moss, Fountain Valley

93901

Pacific Cancer Care, Salinas

94040

El Camino Cancer Center, Mountain View

95403

Redwood Regional Medical Group, Santa Rosa

06606

St. Vincent's Medical Center, Bridgeport

07601

John Theurer Cancer Center at Hackensack University Medical Center, Hackensack

75390-9179

University of Texas Southwestern, Dallas

Sponsors
All Listed Sponsors
collaborator

Premier Research Group plc

UNKNOWN

lead

Wex Pharmaceuticals Inc.

INDUSTRY

NCT01655823 - The Purpose of This Study is to Determine if Tetrodotoxin (TTX) is Effective in the Treatment of Pain Resulting From Chemotherapy Treatment | Biotech Hunter | Biotech Hunter